Related Experiment Video
Updated: Apr 4, 2026

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
Published on: August 1, 2025
Dynamic T-Cell Reprogramming Modulates the Treatment Outcome of Neoadjuvant Immunochemotherapy in Non-Small-Cell Lung
Rui Jin1, Anhao Tian2, Weina Lu1,3
1Key Laboratory of Respiratory Disease of Zhejiang Province Department of Respiratory and Critical Care Medicine Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang China.
Abstract:
Although immunochemotherapy sheds light on neoadjuvant strategies, about two-thirds of patients still respond poorly to perioperative chemoimmunotherapy. Hence, it is crucial to investigate the underlying response mechanism to improve the prognosis of these patients. In this study, we utilized paired pre- and post-neoadjuvant immunochemotherapy samples from non-small-cell lung cancer (NSCLC) patients with single-cell RNA and T-cell receptor (TCR) sequencing to characterize the dynamic changes of T cells in tumor microenvironment. Within nine enrolled patients with distinct pathological assessments, we identified bi-directional mechanisms associated with their pathological responsiveness. One is mediated by a batch of CD8+ T-cell subsets such as effector memory T cells (Tem), effector T cells (Teff), tissue-resident memory T cells (Trm), and exhausted T cells (Tex), exhibiting higher TCR clonality and diversity in responders. CD8+ Tem cells with both novel and pre-existing TCR clonal expansion patterns particularly contributed to improved pathological responses. The other mechanism is through inhibitory Tregs, which showed more novel clonal expansion and enhanced functional profiles in nonresponsive tumors. In conclusion, our findings proposed the bidirectional characteristics of T-cell dynamics for in-depth interpretation of responding mechanisms to neoadjuvant immunochemotherapy of NSCLC.

